Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk?

Heinecke JW.

Nat Med. 2012 Sep;18(9):1346-7. doi: 10.1038/nm.2930. No abstract available.

PMID:
22961165
2.

The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?

Rader DJ, Tall AR.

Nat Med. 2012 Sep;18(9):1344-6. doi: 10.1038/nm.2937. No abstract available.

PMID:
22961164
3.

High-density lipoprotein as a therapeutic target: a systematic review.

Singh IM, Shishehbor MH, Ansell BJ.

JAMA. 2007 Aug 15;298(7):786-98. Review. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
17699012
4.

The rationale for using apoA-I as a clinical marker of cardiovascular risk.

Barter PJ, Rye KA.

J Intern Med. 2006 May;259(5):447-54. Review.

5.

High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.

Tuteja S, Rader DJ.

Clin Pharmacol Ther. 2014 Jul;96(1):48-56. doi: 10.1038/clpt.2014.79. Epub 2014 Apr 8. Review.

PMID:
24713591
6.

Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease.

Brewer HB Jr.

J Clin Endocrinol Metab. 2011 May;96(5):1246-57. doi: 10.1210/jc.2010-0163. Epub 2011 Mar 9. Review.

PMID:
21389140
7.

Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes.

Murakami H, Tanabe J, Tamasawa N, Matsumura K, Yamashita M, Matsuki K, Murakami H, Matsui J, Suda T.

Diabetes Res Clin Pract. 2013 Jan;99(1):30-8. doi: 10.1016/j.diabres.2012.10.022. Epub 2012 Nov 5.

PMID:
23137417
8.

Re-examining the high-density lipoprotein hypothesis.

Tan K.

J Diabetes Investig. 2016 Jul;7(4):445-7. doi: 10.1111/jdi.12487. Epub 2016 Mar 6. No abstract available.

9.

Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis.

Wong NC.

Curr Opin Investig Drugs. 2007 Sep;8(9):718-28. Review.

PMID:
17729183
10.

New targets of high-density lipoprotein therapy.

Nicholls SJ, Nissen SE.

Curr Opin Lipidol. 2007 Aug;18(4):421-6. Review.

PMID:
17620859
11.

Future therapeutic directions in reverse cholesterol transport.

Khera AV, Rader DJ.

Curr Atheroscler Rep. 2010 Jan;12(1):73-81. doi: 10.1007/s11883-009-0080-0. Review.

12.

Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages.

Bultel S, Helin L, Clavey V, Chinetti-Gbaguidi G, Rigamonti E, Colin M, Fruchart JC, Staels B, Lestavel S.

Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2288-95. doi: 10.1161/ATVBAHA.108.175042. Epub 2008 Sep 18.

13.

HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export.

Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L, Jessup W.

Circ Res. 2015 Mar 27;116(7):1133-42. doi: 10.1161/CIRCRESAHA.116.305485. Epub 2015 Jan 14. Erratum in: Circ Res. 2015 Jul 17;117(3):e40.

14.

HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.

Bhatt A, Rohatgi A.

Curr Atheroscler Rep. 2016 Jan;18(1):2. doi: 10.1007/s11883-015-0554-1. Review.

PMID:
26710794
15.

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.

Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, Kulikowski E, Johansson J, Sweeney M, Wong NC.

Atherosclerosis. 2016 Apr;247:48-57. doi: 10.1016/j.atherosclerosis.2016.01.036. Epub 2016 Jan 22.

16.

Small HDL promotes cholesterol efflux by the ABCA1 pathway in macrophages: implications for therapies targeted to HDL.

Heinecke JW.

Circ Res. 2015 Mar 27;116(7):1101-3. doi: 10.1161/CIRCRESAHA.115.306052. No abstract available.

17.

High-density lipoprotein and atherosclerosis: the role of antioxidant activity.

Bandeali S, Farmer J.

Curr Atheroscler Rep. 2012 Apr;14(2):101-7. doi: 10.1007/s11883-012-0235-2. Review.

PMID:
22441969
18.

In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection.

EscolĂ -Gil JC, Rotllan N, Julve J, Blanco-Vaca F.

Atherosclerosis. 2009 Oct;206(2):321-7. doi: 10.1016/j.atherosclerosis.2008.12.044. Epub 2009 Mar 21. Review.

PMID:
19362310
19.

High-density lipoprotein function, dysfunction, and reverse cholesterol transport.

Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD.

Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2813-20. doi: 10.1161/ATVBAHA.112.300133. Review.

20.

Apolipoprotein A-I mimetic peptides.

Hovingh GK, Bochem AE, Kastelein JJ.

Curr Opin Lipidol. 2010 Dec;21(6):481-6. doi: 10.1097/MOL.0b013e3283404507. Review.

PMID:
21042216

Supplemental Content

Support Center